Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Masters of Immunology

  • Masters of Immunology
    Chemokines in Cancer
    Melvyn T. Chow and Andrew D. Luster
    Cancer Immunol Res December 1 2014 2 (12) 1125-1131; DOI:10.1158/2326-6066.CIR-14-0160

Cancer Immunology at the Crossroads: Experimental Immunotherapies

  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
    PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond
    Lauren C. Harshman, Charles G. Drake and Toni K. Choueiri
    Cancer Immunol Res December 1 2014 2 (12) 1132-1141; DOI:10.1158/2326-6066.CIR-14-0193

Priority Brief

  • Priority Brief
    Quantitative Effect of Natural Killer–Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy
    Naoki Tanimine, Yuka Tanaka, Tsuyoshi Kobayashi, Hirotaka Tashiro, Daiki Miki, Michio Imamura, Hiroshi Aikata, Junko Tanaka, Kazuaki Chayama and Hideki Ohdan
    Cancer Immunol Res December 1 2014 2 (12) 1142-1147; DOI:10.1158/2326-6066.CIR-14-0091

    Tanimine and colleagues report that multiplicity of compound KIR-HLA genotypes in blood cells of patients with hepatocellular carcinoma (HCC) correlate with HCC recurrence, supporting therapeutic manipulation of NK-cell activity to compensate for genetic susceptibility to HCC recurrence.

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Pulmonary Sarcoid–like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma
    Natacha Bordry, Carla-Marisa Costa-Nunes, Laurène Cagnon, Philippe O. Gannon, Samia Abed-Maillard, Petra Baumgaertner, Timothy Murray, Igor Letovanec, Romain Lazor, Hasna Bouchaab, Nathalie Rufer, Emanuela Romano, Olivier Michielin and Daniel E. Speiser
    Cancer Immunol Res December 1 2014 2 (12) 1148-1153; DOI:10.1158/2326-6066.CIR-14-0143

    Bordry and colleagues report on a patient with metastatic melanoma, who received repetitive vaccinations with melanoma-associated antigen peptides augmented with CpG as adjuvant, developed autoimmunity without clinical complication, and experienced complete remission and long-term survival for more than 13 years.

Research Articles

  • Research Articles
    Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer
    Shiro Kibe, Shigeru Yutani, Satoru Motoyama, Takanobu Nomura, Natsuki Tanaka, Akihiko Kawahara, Tomohiko Yamaguchi, Satoko Matsueda, Nobukazu Komatsu, Masatomo Miura, Yudai Hinai, Satoshi Hattori, Akira Yamada, Masayoshi Kage, Kyogo Itoh, Yoshito Akagi and Tetsuro Sasada
    Cancer Immunol Res December 1 2014 2 (12) 1154-1162; DOI:10.1158/2326-6066.CIR-14-0035

    Kibe and colleagues report the safety and benefit in a phase II study of 60 pretreated, advanced colorectal cancer (CRC) patients of personalized vaccines comprising HLA-matched peptides selected from preexisting host immunity, providing a new approach of personalized immunotherapy for refractory CRC.

  • Research Articles
    Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist
    Laetitia Fend, Tanja Gatard-Scheikl, Jacqueline Kintz, Murielle Gantzer, Emmanuelle Schaedler, Karola Rittner, Sandrine Cochin, Sylvie Fournel and Xavier Préville
    Cancer Immunol Res December 1 2014 2 (12) 1163-1174; DOI:10.1158/2326-6066.CIR-14-0050

    Fend and colleagues show in an orthotopic mouse model of renal carcinoma that intravenous and not subcutaneous injection of an MVA-MUC1 vaccine with TLR9 ligand (ODN1826) controls tumor growth by efficiently targeting tumor-specific effector/memory lymphocytes to the tumor.

  • Research Articles
    Splenectomy Promotes Indirect Elimination of Intraocular Tumors by CD8+ T Cells That Is Associated with IFNγ- and Fas/FasL-Dependent Activation of Intratumoral Macrophages
    Maxine R. Miller, Jonathan B. Mandell, Kelly M. Beatty, Stephen A.K. Harvey, Michael J. Rizzo, Dana M. Previte, Stephen H. Thorne and Kyle C. McKenna
    Cancer Immunol Res December 1 2014 2 (12) 1175-1185; DOI:10.1158/2326-6066.CIR-14-0093-T

    Miller and colleagues demonstrate a mechanism by which splenectomy promotes rejection of intraocular tumors, which involves an IFNg-and-Fas/FasL-dependent interaction between CD8+ T cells and intratumoral macrophages eliciting severe ocular inflammation that indirectly eliminates intraocular tumors by inducing phthsis.

  • Research Articles
    c-Abl Modulates Tumor Cell Sensitivity to Antibody-Dependent Cellular Cytotoxicity
    Joseph C. Murray, Dalal Aldeghaither, Shangzi Wang, Rochelle E. Nasto, Sandra A. Jablonski, Yong Tang and Louis M. Weiner
    Cancer Immunol Res December 1 2014 2 (12) 1186-1198; DOI:10.1158/2326-6066.CIR-14-0083

    Murray and colleagues used RNAi functional genomics screening of 60 genes from an EGFR gene network and identified that inhibition of c-Abl activity in anti-EGFR-targeted cells can enhance the therapeutic efficacy of cetuximab, an ADCC-promoting anti-EGFR antibody, in colorectal and head and neck cancers.

  • Research Articles
    STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment
    Takayuki Ohkuri, Arundhati Ghosh, Akemi Kosaka, Jianzhong Zhu, Maki Ikeura, Michael David, Simon C. Watkins, Saumendra N. Sarkar and Hideho Okada
    Cancer Immunol Res December 1 2014 2 (12) 1199-1208; DOI:10.1158/2326-6066.CIR-14-0099

    Ohkuri, Ghosh, Kosaka, and colleagues show that a STING-mediated DNA-sensor signaling is involved in IFN induction in the sterile microenvironment of brain tumor that enhances antitumor immunity, providing a proof-of-concept for developing STING agonists for cancer immunotherapy.

  • Research Articles | AuthorChoice
    Granulin–Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity
    Phyllis F.Y. Cheung, Chi Wai Yip, Nicholas C.L. Wong, Daniel Y.T. Fong, Linda W.C. Ng, Angus M.Y. Wan, Chun Kwok Wong, Tan To Cheung, Irene O.L. Ng, Ronnie T.P. Poon, Sheung Tat Fan and Siu Tim Cheung
    Cancer Immunol Res December 1 2014 2 (12) 1209-1219; DOI:10.1158/2326-6066.CIR-14-0096

    Cheung and colleagues show that hepatic oncofetal protein granulin–epithelin precursor (GEP) regulates HCC immunity by modulating MICA and HLA-E expression, which could be reversed by GEP blockade; serum GEP and MICA levels are prognostic and can be used to stratify patients for targeted therapy.

  • Research Articles
    Prognostic Impact of Human Leukocyte Antigen Class I Expression and Association of Platinum Resistance with Immunologic Profiles in Epithelial Ovarian Cancer
    Tasuku Mariya, Yoshihiko Hirohashi, Toshihiko Torigoe, Takuya Asano, Takafumi Kuroda, Kazuyo Yasuda, Masahito Mizuuchi, Tomoko Sonoda, Tsuyoshi Saito and Noriyuki Sato
    Cancer Immunol Res December 1 2014 2 (12) 1220-1229; DOI:10.1158/2326-6066.CIR-14-0101

    Mariya and colleagues analyzed 122 cases of epithelial ovarian cancer (EOC) and identified low expression of HLA class I and low intraepithelial CTL infiltration as independent prognostic factors for poor overall survival for patients with advanced EOC; low HLA class I expression was correlated with platinum resistance.

  • Research Articles | AuthorChoice
    Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes
    Petra Simon, Tana A. Omokoko, Andrea Breitkreuz, Lisa Hebich, Sebastian Kreiter, Sebastian Attig, Abdo Konur, Cedrik M. Britten, Claudia Paret, Karl Dhaene, Özlem Türeci and Ugur Sahin
    Cancer Immunol Res December 1 2014 2 (12) 1230-1244; DOI:10.1158/2326-6066.CIR-14-0108

    Simon, Omokoko, and colleagues developed an integrated approach to retrieve and functionally characterize TCRs from single viral or tumor Ag-reactive T cells and isolated 56 unique Ag-specific TCRs against 39 different epitopes, supporting rational design of T cell-based immunotherapies using this approach.

Acknowledgment to Reviewers

  • Acknowledgment to Reviewers
    Acknowledgment to Reviewers
    Cancer Immunol Res December 1 2014 2 (12) 1245-1245; DOI:10.1158/2326-6066.CIR-2-12-Reviewers

Back to top
PreviousNext
Cancer Immunology Research: 2 (12)
December 2014
Volume 2, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
  • Priority Brief
  • Cancer Immunology Miniatures
  • Research Articles
  • Acknowledgment to Reviewers
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Characterization of Murine Syngeneic Tumor Models
  • PD-L1 in Triple-Negative Breast Cancer
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement